KC
VRPX

Kepos Capital’s Virpax Pharmaceuticals, Inc. Common Stock VRPX Stock Holding History

Kepos Capital’s Portfolio VRPX Stock Details VRPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,000
Closed -$1.67M – 595
2022
Q1 		$1.67M Hold
3,000
– – 0.12% 161
2021
Q4 		$2.57M Hold
3,000
– – 0.21% 167
2021
Q3 		$3.6M Buy
+3,000
New +$6.28M 0.24% 211

Other funds holding VRPX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $43.3B AUM 29.3% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Kepos Capital's VRPX Position: Q2 2022 in Review

Kepos Capital sold out of Virpax Pharmaceuticals, Inc. Common Stock (VRPX) in Q2 2022, closing a stake of 3,000 shares — an estimated $1.67M sold.

Kepos Capital first reported a position in VRPX in Q3 2021 and held it in 3 quarters. The position peaked at $3.6M in Q3 2021. 14 funds tracked by Wall St. Rank hold VRPX as of Q2 2022.

  • Kepos Capital reported no remaining Virpax Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Kepos Capital sold 3,000 Virpax Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $1.67M.
  • Kepos Capital first reported a position in Virpax Pharmaceuticals, Inc. Common Stock in Q3 2021 and held it in 3 quarters.
  • Kepos Capital's Virpax Pharmaceuticals, Inc. Common Stock position peaked at $3.6M in Q3 2021.
  • 14 funds tracked by Wall St. Rank held Virpax Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Kepos Capital's 13F filing for Q2 2022, filed 12 Aug 2022.